Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2013

View Archived Issues

Development and characterization of a second-generation inhibitor of tumorigenesis

Rhythm receives Michael J. Fox Foundation grant to advance RM-131

AAV8 gene therapy corrects experimental primary hyperoxaluria type 1

Camurus receives option-exercise milestone for CAM-2029

AstraZeneca and Merck & Co. enter license agreement for Wee1 kinase inhibitor

New agents for pruritus patented by Leo Pharma

Nektar Therapeutics presents novel polymer conjugated antimicrobial peptide NKTR-223

Novel tricyclic S1P1 modulators disclosed by Bristol-Myers Squibb

Bacteriophage lysin from ContraFect shows activity against S. aureus

Novel CKI inhibitors with circadian rhythm effects identified by Pfizer

Kiadis Pharma completes 5-year follow-up of phase I/II ATIR study

Japanese group presents new EGFR inhibitors for cancer

MEI Pharma acquires PWT-143 from Pathway Therapeutics

Allergan discloses novel S1P1 receptor ligands for pain and other disorders

Omeros reports additional data from OMS-824 program

Association between pulmonary tuberculosis and TLR1 and IL17A genes

NeoStem receives NIH grant to study treatment for skin wounds in scleroderma

Ceftazidime/avibactam combination receives FDA QIDP designation

New Nampt inhibitors synthesized at Genentech and FORMA Therapeutics

Oligomerix receives NIH grant for Alzheimer's disease therapeutic discovery

Piramal Enterprises discloses novel GPR40 agonists

Relypsa reports data on part A of its phase III patiromer trial

Soliris approved in Japan for atypical hemolytic uremic syndrome

Procysbi approved in E.U. for nephropathic cystinosis

Versartis obtains European orphan drug status for VRS-317

Nesp approved in Japan for pediatric patients

Scynexis grants R-Pharm rights to SCY-078 in Russia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.